A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Summary

This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.

Timeline

Start

2022-08-18

Primary completion

2025-02-21

Completion

2027-03

Publications

• Wu L, Wei M, Gao F, Zhang H, Wang J, Xiang F, Gao S, Liu R, Yin J, Guo Y, Liu X, Liang J, Liu S, Li F, Huang D. Safety and Efficacy of Obinutuzumab beta (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial. Neurol Ther. 2026 May 24. doi: 10.1007/s40120-026-00960-w. Online ahead of print.

Drugs

Indications